INFORMATION DISCLOSURE STATEMENT

In compliance with the duty of disclosure under 37 C.F.R. §1.56, and in accordance with the practice under 37 C.F.R. §1.97, the Examiner's attention is directed to the documents listed on the enclosed Form PTO 1449. A copy of each of the listed documents is also enclosed. The filing of this Information Disclosure Statement should not be construed as an admission that any particular listed reference is effective prior art or discloses or renders obvious any aspect of the claimed invention.

This statement is being filed under the provisions of 37 C.F.R. §1.97(c)(2), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance. Please charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

This Amendment and Information Disclosure Statement is being filed together with Petition for Extension of Time. In the event that these papers get separated, this constitutes a Petition for Extension of Time for the minimum period required to effect timely filing of this Amendment and Information Disclosure Statement, together with an authorization to charge any fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper to Deposit Account No. 19-2570.

Respectfully submitted,

Kathryn L. Sieburth Attorney for Applicant Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090
N:\KLS\Cases\B2368C4\draft response 3-26-03.doc

Patent and Trademark Office B 2368C4 APPLICANT Hindley, et al. FILING DATE June 1, 1995 U.S. PATENT DOCUMENTS Examiner Initial Pocument Number FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS Class Subclass Filing Date If Appropriate							heet <u>1</u> 0	of <u>1</u> .
BY APPLICANT JULE 3 1993 We several sheets it necessary) U.S. PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS Document Number Date Country Closs Subclass Filing Date It Appropriate POTHER DOCUMENTS (Including Author, Title Date, Pertinent Pages, Etc.) Black's Medical Dictionary, C.W.H. Havard, Eds., pp. 187-190 & 347 (1987). The Textbook of Medicine, James B. Wyngaarden, Ed., pp. 1360-1381 (1988). Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methyleyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," Dibetes 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER Initial if citation considered, whether or not citation is in conformance with MPEP 509. Draw line through	Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office		ATTY, DOCKET NO. B2368C4					
BY APPLICANT Hindley, et al. Filing DATE June 1, 1995 1626	VINFOR	MATION DISCLOSU	RE STATEMENT	APPLICANT				
### PAPER Introduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methyleyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63.287, Ciglitazone). A New Antidiabetic Agent." Dibeters 32(9), 804-810 (September 1983) Filing Date Name Class Subclass Filing Date Appropriate				Hindley, et al.				
U.S. PATENT DOCUMENTS Lorinor Document Dote Name Class Subclass Filing Date Mappropriate	→ \			FILING DATE GROUP			· · ·	
Document Date Name Class Subclass Filing Date It Appropriate	Q (ับ รู๊อ several sheets if n	ecessary)	June 1, 1995	June 1, 1995 1626			
Document Date Name Class Subclass Filing Date It Appropriate	Ca	-						
FOREIGN PATENT DOCUMENTS Document Number Date Name Class Subclass Filing Date If Appropriate	TRANS							
FOREIGN PATENT DOCUMENTS Document Date Country Class Subclass Iranslation Yes No			U.S. PATENT	DOCUMENTS				
POREIGN PATENT DOCUMENTS Document Date Country Class Subclass Translation Yes No	1 1			Name	Class	1		
Document Number Date Country Class Subclass Iranslation Yes I No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Black's Medical Dictionary, C.W.H. Havard, Eds., pp. 187-190 & 347 (1987). The Textbook of Medicine, James B. Wyngaarden, Ed., pp. 1360-1381 (1988). Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," Dibetes 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER. Initial if citation considered, whether or not citation is in conformance with MPEP 609, Draw line through	Initial	Number		If Ap		It Appre	<u>ppropriate</u>	
Document Number Date Country Class Subclass Iranslation Yes I No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Black's Medical Dictionary, C.W.H. Havard, Eds., pp. 187-190 & 347 (1987). The Textbook of Medicine, James B. Wyngaarden, Ed., pp. 1360-1381 (1988). Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," Dibetes 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER. Initial if citation considered, whether or not citation is in conformance with MPEP 609, Draw line through								
Document Number Date Country Class Subclass Iranslation Yes I No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Black's Medical Dictionary, C.W.H. Havard, Eds., pp. 187-190 & 347 (1987). The Textbook of Medicine, James B. Wyngaarden, Ed., pp. 1360-1381 (1988). Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," Dibetes 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER. Initial if citation considered, whether or not citation is in conformance with MPEP 609, Draw line through								
Document Number Date Country Class Subclass Iranslation Yes I No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Black's Medical Dictionary, C.W.H. Havard, Eds., pp. 187-190 & 347 (1987). The Textbook of Medicine, James B. Wyngaarden, Ed., pp. 1360-1381 (1988). Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," Dibetes 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER. Initial if citation considered, whether or not citation is in conformance with MPEP 609, Draw line through		- ···						
Document Number Date Country Class Subclass Iranslation Yes I No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Black's Medical Dictionary, C.W.H. Havard, Eds., pp. 187-190 & 347 (1987). The Textbook of Medicine, James B. Wyngaarden, Ed., pp. 1360-1381 (1988). Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," Dibetes 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER. Initial if citation considered, whether or not citation is in conformance with MPEP 609, Draw line through			FOREIGN PATE	NT DOCUMENTS				
DITER DOCUMENTS (Including Author, Title, Date, Perlinent Pages, Etc.) Black's Medical Dictionary, C.W.H. Havard, Eds., pp. 187-190 & 347 (1987). The Textbook of Medicine, James B. Wyngaarden, Ed., pp. 1360-1381 (1988). Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methyleyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," Dibetes 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER. Initial if citation considered, whether or not citation is in conformance with MPEP 609, Draw line through		Document			Class	Subclass	Transl	lation
Black's Medical Dictionary, C.W.H. Havard, Eds., pp. 187-190 & 347 (1987). The Textbook of Medicine, James B. Wyngaarden, Ed., pp. 1360-1381 (1988). Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2.4-dione (ADD-3878, U-63.287, Ciglitazone). A New Antidiabetic Agent," Dibetes 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through		Number		·			Yes I	No.
Black's Medical Dictionary, C.W.H. Havard, Eds., pp. 187-190 & 347 (1987). The Textbook of Medicine, James B. Wyngaarden, Ed., pp. 1360-1381 (1988). Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2.4-dione (ADD-3878, U-63.287, Ciglitazone). A New Antidiabetic Agent," Dibetes 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through								1
Black's Medical Dictionary, C.W.H. Havard, Eds., pp. 187-190 & 347 (1987). The Textbook of Medicine, James B. Wyngaarden, Ed., pp. 1360-1381 (1988). Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2.4-dione (ADD-3878, U-63.287, Ciglitazone). A New Antidiabetic Agent," Dibetes 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through							<u> </u>	
Black's Medical Dictionary, C.W.H. Havard, Eds., pp. 187-190 & 347 (1987). The Textbook of Medicine, James B. Wyngaarden, Ed., pp. 1360-1381 (1988). Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2.4-dione (ADD-3878, U-63.287, Ciglitazone). A New Antidiabetic Agent," Dibetes 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through			L				·	
Black's Medical Dictionary, C.W.H. Havard, Eds., pp. 187-190 & 347 (1987). The Textbook of Medicine, James B. Wyngaarden, Ed., pp. 1360-1381 (1988). Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2.4-dione (ADD-3878, U-63.287, Ciglitazone). A New Antidiabetic Agent," Dibetes 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through								
The Textbook of Medicine, James B. Wyngaarden, Ed., pp. 1360-1381 (1988). Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2.4-dione (ADD-3878, U-63.287, Ciglitazone), A New Antidiabetic Agent," <i>Dibetes</i> 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6.288.095 EXAMINER DATE CONSIDERED		OTHER DOC	CUMENTS (Including Au	thor, Title. Date, <u>Pertine</u>	ent Pages, E	tc.)		
The Textbook of Medicine, James B. Wyngaarden, Ed., pp. 1360-1381 (1988). Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2.4-dione (ADD-3878, U-63.287, Ciglitazone), A New Antidiabetic Agent," <i>Dibetes</i> 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6.288.095 EXAMINER DATE CONSIDERED								
Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," <i>Dibetes</i> 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through		Black's Medical	Dictionary, C.W.H. I	Havard, Eds., pp. 187	7-190 & 34	7 (1987).		
Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," <i>Dibetes</i> 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through								
Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," <i>Dibetes</i> 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through								
Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," <i>Dibetes</i> 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through		The Trendle wale of	Madiaina Innan D	Wangaandan Ed. m	- 1260 12	01/1000		
methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," <i>Dibetes</i> 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through		The Textbook of	Medicine, James B.	wyngaarden, Ed., pp	9. 1300-13	81 (1986).		
methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," <i>Dibetes</i> 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through								
methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," <i>Dibetes</i> 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through								
methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," <i>Dibetes</i> 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through		Fujita et al., "Red	duction of Insulin Re	sistance in Obese and	d/or Diabe	tic Animals	by 5[4-6	(1-
Ciglitazone), A New Antidiabetic Agent," <i>Dibetes</i> 32(9), 804-810 (September 1983) Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through								
Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through		-	• •					
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through		Cigittazone), A r	New Antidiabetic Age	ent, <i>Dibetes</i> 52(9), 6	50 4 -610 (5	eptember r	903)	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through								
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through								
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through		Patent Certificati	on Notice, July 11, 2	003. Portions relatin	g to U.S. 6	,288,095		
-EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through					C			
-EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through	EXAMINER			DATE CONSIDERED				
-EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.								
citation if not in conformance and not considered. Include copyof this form with next communication to applicant.	EVANABLED: 1-	itial if altation and de-	rad whathar areast =:t=	ation is in application	With MIDED	600: Draw line	n through	
	citation if not i	n conformance and r	rea, whether or not clic not considered. Include	e copyof this form with	next commi	unication to (applican:	.†.